Selling your chemicals or life sciences business: why a slow process can erode value, and how to avoid it

CCD Partners • Nov 05, 2018

If you are thinking about selling your privately-owned chemicals or life sciences business, it’s likely that there are several items vying for the top spot on your list of priorities.

Amongst maximising price, optimising deal structure, and securing a good home for employees – there are many factors at play in a typical divestment strategy.

It’s less common, however, for speed to rank highly as a concern for many sellers. Finding the right deal is rightly considered as the primary objective, and an emphasis on completing the process quickly may seem counter-intuitive to the concept of working patiently towards a successful completion.

In fact, speed has a critical role to play – in particular, minimising the length of time from first talking to potential buyers through to completion, in other words, your time “on the market”.

The more time a business is “on the market” the higher the risks and costs.

What are the risks and costs?

The following risks and costs all generally increase with time:

  • Transaction costs (lawyers, datarooms, accountants, M&A advisors and others)
  • Management distraction from their day jobs
  • Customer and supplier hesitance to trade with a company “on the market” – often overestimated, but still a factor in some cases
  • An unexpected issue arising that jeopardises the deal (e.g. profit dip, or Brexit votes!)
  • ‘Deal fatigue’ wearing down all involved (I was once brought in part-way through one deal that ran in total to an enthusiasm-sapping 30 months…)

Top 5 deal speed strategies

The overall aim is to minimise the time the business is “on the market”. This means every stage of a successful sale - from business preparation through buyer engagement and due diligence - should be optimised with this aim in mind.

  1. Prepare materials thoroughly in advance of approaching potential buyers - marketing materials and key backing data should be in almost final form before going to market. I find sellers can experience frustration during this period as they are keen for progress, but experience shows time spent in this stage can be invaluable later.
  2. Research and plan your engagement strategy - many buyers will publish their growth strategies and priorities, others you or your advisors may know already. Research and informal conversations (i.e. without revealing a specific project) can a) provide guidance on what potential buyers would like to see, and b) tell you if the timing is right – it is better to pause before going to market than to frustrate buyers with a stop-start approach (on one of my projects I was aware that the head of M&A at our most likely buyer was about to change, so we delayed a month to let the incoming executive get his feet under the desk).
  3. State timetable aims to all parties in advance and maintain momentum - it is crucial that your deal team controls the process and drives it forward as best fits your interests. Effective communication is key here as even keen, motivated buyers need fair warning to get all their own ducks in a row at each stage of the process.
  4. Advance multiple workstreams simultaneously - in theory, negotiations, buyer due diligence, and legal drafting can all be progressed concurrently, and these phases can be sped up by pro-active sell-side work (e.g. drafting the SPA or providing a vendor DD pack). This shouldn’t be seen as the seller being “too keen”, it is simply good process management and the benefits usually far outweigh the costs if you are committed to finding a deal.
  5. Be prepared to sacrifice complete certainty in exchange for speed - sometimes a choice must be made between spending additional weeks locking down the terms of a deal and driving forward towards the close. A careful cost/benefit assessment should be made for any proposed delays or extensions.

Key to capturing value

Once “on the market”, speed of execution ranks among several key factors which can have a dramatic impact on the ability of shareholders to realise the full value of their business.

Careful planning and preparation for a sale process that moves swiftly once buyers are engaged, minimises opportunities for value erosion and deal failure. As Benjamin Franklin once said –

“An ounce of prevention is worth a pound of cure.”

CCD Partners is a consultancy specialised in corporate transformations in small and mid-market chemicals and life sciences businesses.

To organise a call with one of our partners please email contact@ccdpartners.com

Receive M&A news relevant to your business

At critical moments our clients engage us to provide pre-publicity "off-market" intelligence to give them the edge over the competition - we also provide up-to-the-minute public or "on-market" intelligence for free

Contact Us

We're committed to your privacy. CCD Partners uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe at any time. For more information, please see our Privacy Policy.   

RECENT POSTS

By Matt Dixon 05 Dec, 2022
Market leading provider of formulated chemical process aids and foam control, PennWhite has been acquired by Manali Petrochemicals, part of the AM International Holdings group.
By Matt Dixon 02 Dec, 2022
Global source of industrial gas news, views, and debate, gas world has been sold by John and Karen Raquet to the senior management team in an MBO, backed by Mobeus Equity Partners.
By Matt Dixon 13 Sep, 2022
Polyblend UK Ltd is one of the market leaders in PVC based polymers. We are experts in manufacturing a comprehensive range of liquid plastisol and dispersion systems, complemented by our Speciality Distribution business supplying plasticisers, resins and PVC additives.
By Matt Dixon 05 May, 2022
GFBiochemicals is a sustainable chemicals company that produces levulinic acid derivatives at commercial scale directly from biomass. Having perfected its technology, product, and certification, the company is entering a new phase of commercialization.
By CCD Partners 20 Apr, 2022
In the latest episode of the Chemical Transformations podcast , CCD Partners' Managing Partner Matt Dixon speaks with Ted Clark, former President and CEO of Royal Adhesives & Sealants, discussing his new book "Shipping Clerk to CEO: The Power of Curiosity, Will, and Self Directed Learning”. The book tells the story of Clark’s remarkable career journey from entry-level worker to CEO of a $240m chemical company by the age of 42.
By Matt Dixon 04 Feb, 2022
Esteve Química purchases one of the UQUIFA Group's two pharmaceutical fine chemicals plants in Barcelona.
By Matt Dixon 04 Feb, 2022
Specialty materials manufacturer Vertellus has acquired Polyscope Polymers B.V., a global leader in specialty additives for coatings, electronics applications, and engineering polymers.
By Matt Dixon 01 Nov, 2021
Biosynth Carbosynth is a fully hybrid Research Products, Life Sciences Reagents and Custom Synthesis and Manufacturing Services Company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products.
By CCD Partners 12 Oct, 2021
Steve Allin co-founded Charnwood Molecular with Phil Page in 1998. 22 years later, the business has evolved dramatically from its origins as a spinout of Loughborough University. Backed by a partnership with Synova Capital, the company is now preparing to move into a former AstraZeneca research facility and has already completed its first M&A deal, acquiring Aurelia Bioscience in summer 2021. CCD Partners’ Matt Dixon spoke with Steve about the journey from full-time academia to running a high-growth market leader.
By Matt Dixon 24 Sep, 2021
Aspire was founded in 2009. Aspire has an asset-light business model that focuses on R&D, business development and sales and marketing, while outsourcing manufacturing and distribution to specialist third parties. For more details see www.aspirepharma.co.uk.
Show More
Share by: